COVID-19 highlights the acute need for non-invasive, point-of-care, remote monitoring

hemodynamic measurement solutions. Find out how CPS meets the need.

Sensydia in the news

October 20, 2026

Sensydia Appoints Brit Gould as Chief Commercial Officer

Sensydia today announced the appointment of Brit Gould as Chief Commercial Officer. Gould has led Sensydia’s commercialization efforts since 2024 as Vice President, Marketing and Market Access. The appointment follows the company’s recent financing and is part of building the team that will take the Cardiac Performance System (CPS™) through its ACOUSTIC-1 study to commercial launch.

Learn More

Sensydia Appoints Brit Gould as Chief Commercial Officer to Lead Commercialization of the Cardiac Performance System (CPS™)

Split image. Left, in grayscale: a hospital catheterization lab, labeled “Invasive: Cath Lab.” Right, in blue: a patient lying down with Sensydia CPS sensors on his chest and a tablet showing pulmonary pressure results, labeled “Non-invasive: Point of Care.”

Sensydia Secures Oversubscribed Funding to Deliver Groundbreaking Cardiac Performance System to the Office, Hospital, and Clinic

CPT® code 1036T for non-invasive hemodynamic assessment.

Sensydia in the news

Sensydia Appoints Brit Gould as Chief Commercial Officer

Sensydia Appoints Brit Gould as Chief Commercial Officer to Lead Commercialization of the Cardiac Performance System (CPS™)

Sensydia Secures Oversubscribed Funding to Deliver Groundbreaking Cardiac Performance System to the Office, Hospital, and Clinic

A New Reimbursement Pathway for Non-invasive Hemodynamic Assessment

Sensydia Announces American Medical Association Category III CPT® Code for Noninvasive AI Hemodynamic Assessment

Sensydia Awarded Second Phase of $3M NIH Grant Award to Demonstrate Clinical Utility of Cardiac Performance System (CPS™)

Sensydia Appoints Rusty Page as President and Chief Operating Officer to Support Growth and Commercialization of the Cardiac Performance System (CPS™)